This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weiss, K. Articles by Lapointe, J. R. Search for Related Content PubMed PubMed Citation Articles by Weiss, K. Articles by Lapointe, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 11 1995, 2411-2414, Vol 39, No. 11
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa

K Weiss and JR Lapointe
Department of Microbiology and Immunology, Hopital Ste-Justine, Universite de Montreal, Quebec, Canada.

Previous studies have demonstrated synergy between an aminoglycoside and a beta-lactam for treating Pseudomonas aeruginosa infections. Cystic fibrosis patients are prone to infection by this bacterium, which becomes very resistant with recurrent antibiotic treatments. The purpose of this study was to evaluate the susceptibility patterns of 122 isolates of P. aeruginosa isolated from cystic fibrosis patients to five individual antibiotics (tobramycin, ceftazidime, piperacillin, ticarcillin, and imipenem) and to four antibiotic combinations (tobramycin associated with one of the other antibiotics). Strains were selected because of their resistance to individual antimicrobial agents, which ranged from 21.3% for imipenem to 56.5% for tobramycin. By using an automated broth microdilution method, we were able to demonstrate synergy against 39 strains (32%) with tobramycin- ticarcillin, against 38 strains (31%) with tobramycin-piperacillin, against 47 strains (39%) with tobramycin-ceftazidime, and against 23 strains (19%) with tobramycin-imipenem. Of the 122 isolates, 77 (63%) were rendered significantly susceptible to at least one of the four antibiotic combinations by synergy. These results suggest that when appropriate technology is available, susceptibility to antibiotic combinations greatly improves the guide to antibiotic therapy for infections due to P. aeruginosa in cystic fibrosis patients.

This article has been cited by other articles:

• Foweraker, J. E., Laughton, C. R., Brown, D. F., Bilton, D. (2009). Comparison of Methods To Test Antibiotic Combinations against Heterogeneous Populations of Multiresistant Pseudomonas aeruginosa from Patients with Acute Infective Exacerbations in Cystic Fibrosis. Antimicrob. Agents Chemother. 53: 4809-4815 [Abstract] [Full Text]  
• Flume, P. A., Mogayzel, P. J. Jr., Robinson, K. A., Goss, C. H., Rosenblatt, R. L., Kuhn, R. J., Marshall, B. C., and the Clinical Practice Guidelines for Pulmonary, (2009). Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am. J. Respir. Crit. Care Med. 180: 802-808 [Abstract] [Full Text]  
• Oie, S., Uematsu, T., Sawa, A., Mizuno, H., Tomita, M., Ishida, S., Okano, Y., Kamiya, A. (2003). In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52: 911-914 [Abstract] [Full Text]  
• Mayer, I., Nagy, E. (1999). Investigation of the synergic effects of aminoglycoside- fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.. J Antimicrob Chemother 43: 651-657 [Abstract] [Full Text]